Skip to content
Study details
Enrolling now

Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer

SOFIE
NCT IDNCT07217704ClinicalTrials.gov data as of Apr 2026
Phase

Phase 3

Target enrollment

200

Study length

about 1.8 years

Ages

18+

Locations

10 sites in CA, FL, IN +3

What this study is about

Researchers are testing whether a new imaging test, called 18F-FAPI PET/CT, can help find cancer that has spread (metastasis) in people with gastric or esophageal cancer. The trial will involve using this imaging test to see if it accurately detects metastatic disease.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take [18F]FAPI-74 PET/CT

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Standard

How treatment is administered

Treatment Assignment
All receive treatment

Everyone gets the investigational treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Endpoints

Secondary: Incidence and severity of adverse events using CTCAE v5., Number of participants with treatment-related adverse events as assessed by blood pressure changes, Number of participants with treatment-related adverse events as assessed by body temperature changes, Number of participants with treatment-related adverse events as assessed by pulse rate, Number of participants with treatment-related adverse events as assessed by respiration rate